Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Wendy Straitwell

Nurse Practitioner Port Charlotte, FL Nurse Practitioner

NPI 1588041495 CMS profile 10801929

19531 Cochran Blvd, Port Charlotte, FL 33948

Open in the dashboard

General payments

$8,226

494 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Wendy Straitwell of Port Charlotte, FL is reported in the CMS Open Payments database as having received $8,226 across 494 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,744 100
2024 General $1,498 85
2023 General $1,569 94
2022 General $1,685 103
2021 General $1,730 112

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Wendy Straitwell
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Wendy Straitwell were reported at $1,744. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Wendy Straitwell Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $1,730 $135 $40–$426 $132
2022 $1,685 $152 $48–$470 $149
2023 $1,569 $166 $54–$529 $160
2024 $1,498 $173 $55–$556 $164
2025 $1,744 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novo Nordisk Inc $1,340 83 payments
  2. AbbVie, Inc. $1,272 71 payments
  3. GlaxoSmithKline, LLC. $955 76 payments
  4. Amgen Inc. $521 40 payments
  5. Esperion Therapeutics, Inc. $505 27 payments
  6. Pfizer Inc. $493 23 payments
  7. Lilly USA, LLC $483 29 payments
  8. Astellas Pharma US Inc $236 12 payments
  9. IBSA Pharma Inc. $206 11 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $202 12 payments
  11. Other $2,013 110 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,226 494 payments
Products named General payments · program years 2021–2025
  1. RYBELSUS $917 53 payments
  2. Ozempic $913 54 payments
  3. TRELEGY ELLIPTA $804 64 payments
  4. QULIPTA $748 42 payments
  5. NEXLETOL $505 27 payments
  6. NURTEC ODT Pain $410 19 payments
  7. ZAVZPRET $347 16 payments
  8. UBRELVY $325 18 payments
  9. Otezla $317 26 payments
  10. NURTEC ODT Primary Care $276 17 payments
  11. Other $5,479 324 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 123 drugs

Part D claims

6,921

Median for Nurse Practitioner: 389

Drug cost

$685,276

Median for Nurse Practitioner: $21,885

Branded share of claims

16.1%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 87 $129,610
Eliquis Apixaban Brand 65 $87,009
Ozempic Semaglutide Brand 54 $77,276
Mounjaro Tirzepatide Brand 57 $63,513
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 45 $59,901
Rybelsus Semaglutide Brand 26 $42,711
Trulicity Dulaglutide Brand 23 $32,067
Januvia Sitagliptin Phosphate Brand 24 $30,094
Farxiga Dapagliflozin Propanediol Brand 15 $18,967
Xarelto Rivaroxaban Brand 18 $17,496

The 10 drugs with the highest cost, of 123 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 70 billing codes

Paid by Medicare

$91,366

Of which drugs: $4,164

Medicare patients

282

Average age 73

Services billed

3,885

187 women, 95 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 48%
Depression 27%
Chronic kidney disease 26%
Ischemic heart disease 24%
COPD 21%
Diabetes 20%
Atrial fibrillation 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 19 19 $1,535

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 32 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
QULIPTA
  • AbbVie, Inc. $189
$189 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $173
$173 45 —
RYBELSUS
  • Novo Nordisk Inc $114
$114 26 —
VRAYLAR
  • AbbVie, Inc. $95
$95 — —
NURTEC ODT
  • PFIZER INC. $92
$92 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 32 with Patron

Records

494 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record